anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This group will consist of individuals diagnosed with carpal tunnel syndrome (CTS) who are 18 years of age or older and who are able to provide informed consent to participate in the study. The group will be recruited from a single center and will be asked to complete the Jebsen-Taylor Hand Function Test and the Nine-Hole Peg Test twice, with a 1-week interval between the two assessments. The aim is to establish the test-retest reliability of these tests in individuals with CTS. The group will include at least 50 participants and will be diverse in terms of age, gender, and race/ethnicity to ensure that the study findings are generalizable to a broader population.
Subjects enrolled into the study will be randomly assigned to one of 2 groups. The first group will receive one hour of conventional gait training, consisting of lower extremity strengthening exercises, stretching, and full weight bearing walking as tolerated, with appropriate physical assistance from a therapist. The second group will receive walking therapy using a Lokomat, which is a special treadmill that works in conjunction with 2 light-weight robotic arms that assists the subject to move their legs while they try to walk on the treadmill. Some of the subject's body-weight will be supported using a harness. During Lokomat training sessions, subjects will receive feedback of their walking performance on a computer monitor to help them walk. Both groups will be trained for 8-10 weeks, 3 times per week, for 1 hour training sessions (24 total sessions). Resources for transportation to the National Rehabilitation Hospital will be provided to all study participants.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of suppressing and preventing a contact dermatitis and excellent in hair dyeing property by containing a specific plant extract material in an oxidizable hair dyeing agent. SOLUTION: This hair dyeing composition contains the following components. (A) an oxidizable dye or a salt thereof (e.g.; para-phenylene diamine). (B) an oxidizer (e.g.; hydrogen peroxide). (C) one or more kinds of plant extracts selected from Ginkgo biloba, Phyllanthus niruri and Rosemarinus officinalis. The plant extract is extracted by using an organic solvent and a usual extraction method and it is preferable to contain the Ginkgo and Ph. niruri extracts by 0.1-5wt.% and the R. officinalis extract by 0.5-5wt.% based on the total amount of the first component. By applying the composition to the hair, it can sufficiently dye the white hair in an excellent hair dyeing property without developing an allergic contact dermatitis.
Patients being referred for the routine Equilibrium Radionuclide Angiocardiography (ERNA) for assessment of their left ventricular function will be asked to participate in the study. All patients will be asked to sign the consent form. Patients will be given a choice to participate in either or both studies (i.e. ERNA plus ACGBS or ERNA plus ACGBS and 3 DE).
A solution suitable as a hypothermic blood substitute for replacing blood in euthermic subjects during surgery are provided. The blood substitute contains a purge solution and a maintenance solution, the latter of which is useful for organ preservation. The purge solution contains an aqueous solution of electrolytes at physiological concentrations, a macromolecular oncotic agent, a biological pH buffer effective under physiological and hypothermic conditions, a simple sugar, and a substrate for the regeneration of ATP. The maintenance solution contains a second aqueous solution of electrolytes containing potassium ions at a concentration range of from 35 to 45 mM, sodium ions at a concentration range of from 80 to 120 mM, magnesium ions at a concentration range of from 2 to 10 mM, chloride ions at a concentration range of from 15 to 20 mM, and calcium ions at a concentration range of from 0.01 to 0.1 mM, an impermeant anion, mannitol, a macromolecular oncotic agent, at least one simple sugar, a substrate for the regeneration of ATP, and a biological pH buffer effective under physiological hypothermic conditions. Glutathione is an optional but preferred additive. The blood substitute solutions are also useful for preserving organs for later transplantation in subjects. Skin may be preserved in the maintenance solutions for extended periods under refrigeration.
The whole egg powder arm will be part of our food product intervention. Food products created using whole egg powder will be provided and consumed 10x/week for 9 months. Each food item will contain the equivalent of one whole egg.
PROBLEM TO BE SOLVED: To obtain an alignate impression material containing a specific ester, capable of imparting the resultant impression with humectancy so as to prevent moisture evaporation therefrom to effect prevention of decline in its elasticity with the lapse of time. SOLUTION: This alginate impression material is obtained by incorporating 0.3-10wt.% of a sucrose fatty acid ester (pref. an ester of sucrose and a 8-22C fatty acid with the content of monoester form at 40% or higher, or with an HLB number at least 7) in a composition pref. comprising an alginate, gelling agent. gelling regulator and filter. This impression material is easy to handle because of minor concern for the breakage of its small parts even in demolding a model gypsum.
### Cardiovascular Thrombotic Events 

Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur. 

There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see WARNINGS, GI Effects). 

Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial infarction and stroke (see CONTRAINDICATIONS). 

### Hypertension 

NSAIDs, can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including diclofenac sodium delayed-release tablets, should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy. 

### Congestive Heart Failure and Edema 

Fluid retention and edema have been observed in some patients taking NSAIDs. Diclofenac should be used with caution in patients with fluid retention or heart failure.
PURPOSE: A composition containing phospholipids for preventing alopecia is provided to easily remove sebum and to prevent sebum solidification. CONSTITUTION: A composition for preventing alopecia or promoting hair growth contains phospholipids as an active ingredient. The phospholipid is isolated from animal such as cow or pig. The phospholipids are isolated from an animal lung. The phospholipids are dipalmitoylphosphatidyl choline, phophatidyl choline, phosphatidyl serine, or phosphadityl inositol. The composition further contains organic acid containing bivalent cations or carboxyl groups or salt thereof. The composition is a pharmaceutical composition or cosmetic composition. The cosmetic composition is used in the form of a hair tonic, hair cream, hair lotion, hair shampoo, hair rinse, hair conditioner, hair spray, pomade, powder, or gel.
Keto ro lac t ro met ham ine op htha lm ic so lut i on 0.5% is a m ember of the pyrrolo-­pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthal mic use. Its che mical na me is (±)-5-Benzoyl-2, 3-dihydro-1H pyrrolizi ne-1-carboxylic acid co m pound with 2-a mino-2-(hydroxy methyl)-1,3-propanediol ( 1:1) and it has the following structure:

  


  
Keto ro lac t ro met ham ine op htha lm ic so lut i on is supplied as a sterile isotonic aqueous 0.5% solution, with a pH of 7.4. Keto ro lac t ro met ham ine op htha lm ic so lut i on is a race mic m ixture of R-(+) and S-(-)- ketor olac tro metha mine. Ketorol ac tro methamine may exist in t hree cr ystal for ms. All for ms are equally soluble in water. The pKa of ketorolac is 3.5. This white to o ff-white c rystalline su bstance discolors on prolonged exposure to light. The m o lecular weight of ketorolac tro metha mine is 376.41. The os molality of keto ro lac t ro met ham ine op htha lm ic so lut i on is 290 m O s mol/kg.

  


Each mL of ketorolac tromethamine ophthalmic solution contains: Active: ketorolac tromethamine USP 0.5%. Preservative: benzalkonium chloride solution (50%) NF 0.02%. Inactives: edetate disodium USP 0.1%; octoxynol 40; water for injection USP; sodium chloride USP; hydrochloric acid NF and/or sodium hydroxide NF to adjust the pH.
It is intended to provide a Mallotus philippensis extract containing rottlerin which is highly soluble in water. It is also intended to improve the convenience in the process for producing the above extract by avoiding coloration in a filter and/or a pipe employed in the steps of extraction and filtration to thereby lower the washing cost, facilitating the introduction of freeze-drying, etc. In extracting a Mallotus philippensis plant with water/alcohol to give a colorant extract, a base component is added to thereby remarkably elevate the solubility of the Mallotus philippensis extract in water. Thus, the extraction ratio can be improved and the washing procedure in production or powdering of the extract can be easily performed. Moreover, the solubility in water of the extract thus obtained can be improved. ® KIPO & WIPO 2007
Obstetric hemorrhage remains the leading cause of maternal death worldwide (2). The most common culprits are uterine atony, placental disorders, and delivery trauma. Current detection and management of hemorrhage is heavily based on clinical judgment and laboratory results. Interventions such as fluid resuscitation and blood transfusion are often initiated after a significant hemorrhage has already taken place. Early detection and treatment of this potentially life threatening obstetric complication is of upmost importance in the field of obstetrics. Traditional methods for assessing hemoglobin levels involve collecting the patient's blood and sending it to the laboratory for analysis via complete blood count (CBC). This involves a delay and often patients are continuing to hemorrhage while the CBC is being processed. Novel technology has recently been approved by the FDA, which can continuously assess hemoglobin levels via a non-invasive monitor. This device works as a pulse oximeter, which is placed on the index finger and uses infrared technology to estimate hemoglobin levels (1). Despite its validation and use in many patient populations such as trauma, neurosurgery and orthopedic surgery, data is lacking in an obstetric population. The investigator's hypothesis is that this device will enable clinicians detect hemorrhage early and initiate resuscitation such as fluid and/or blood transfusion before significant hemorrhage has taken place. This study will be a proof of concept prospective cohort study, in which the investigators will attempt to detect the association between intra-operative and postoperative continuous non-invasive hemoglobin monitoring and postpartum decrease in hemoglobin.

Women undergoing primary cesarean delivery after failed induction of labor or repeat cesarean delivery after failed TOLAC (trial of labor after cesarean delivery), will be eligible for participation in this study. Prior to cesarean, all patients will have a CBC drawn. Masimo non-invasive hemoglobin monitor will be placed on their finger during delivery and remain in place until discharge from the recovery room. All patients will have CBC drawn on post operative day 1, as is the standard of care at our institution. Based on the drop in hemoglobin from pre-op to post-op day 1, patients will be separated into quartiles. The quartile with the highest drop in hemoglobin will be the "cases" and compared to the remainder of the quartiles or "controls." In addition, values obtained from the non-invasive monitor will be compared to those obtained from CBC.
Multidimensional mobility exercises were given at exercise unit of Dokuz Eylul University School of Physical Therapy, Izmir, Turkey. Group of 6-7 patients were instructed by a specialized physiotherapist twice in a week for eight weeks. The room temperature was 23-240C. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
BACKGROUND Obesity hypoventilation syndrome (OHS) is characterized by hypercapnia in obese patients, with acute hypercapnic respiratory failure often worsened by various conditions. Managing super-super obese patients presents complex challenges in critical care. Our case report details the successful treatment of acute respiratory failure in a patient with a body mass index (BMI) over 80 kg/m², highlighting the importance of comprehensive, multidisciplinary care in the Intensive Care Init (ICU). CASE REPORT A 39-year-old man with a BMI of 81.1 kg/m² presented to our emergency department with respiratory distress, altered consciousness, and an inability to move independently. Arterial blood gas analysis revealed severe hypercapnia and hypoxemia, indicating decompensated OHS. Laboratory tests and computed tomography scans suggested his condition was exacerbated by pneumonia and congestive heart failure. The patient was managed in the ICU with endotracheal intubation, mechanical ventilation, and esophageal pressure monitoring. In addition to antibiotics, diuretics were used to manage fluid balance. His care included multidisciplinary support with nutritional management and active physiotherapy. After 15 days, he was weaned from the ventilator and discharged from the ICU on day 20, continuing rehabilitation until he was discharged home on day 60. CONCLUSIONS This case report describes the successful treatment of acute hypercapnic respiratory failure from decompensated OHS in a super-super obese patient. Addressing the underlying conditions and tailoring clinical practices to the patient's specific needs, especially regarding ventilatory support, fluid balance, and nutrition, were crucial. A collaborative multidisciplinary approach was essential for improving outcomes.
As described, standard therapy for patients with primary CNS lymphoma is not based on a high level of evidence yet, and studies in elderly patients with this disease are very limited. Based on the Korea National Cancer Incidence Database, it is estimated that about 100 \~ 150 cases of primary central nervous system lymphoma are diagnosed per year in Korea, but there is no analysis through prospective studies. As described previously, MTX monotherapy in elderly patients is relatively safe and does not reduce clinical utility. Although the autologous therapy may consider autologous stem cell transplantation, it is difficult to apply in elderly patients. Brain radiation therapy is not a primary consideration because it may cause neurological sequelae, especially in elderly patients. High-dose cytarabine is a safely administered drug that has been used extensively in clinical studies involving the treatment of elderly patients.Rituximab has not been studied prospectively for medications, doses, and intervals that are expected to play a role in patients with primary CNS lymphoma, as described above, and may be caused by reducing the number of cytotoxic anticancer drugs in elderly patients And to reduce the treatment effect.

Therefore, the authors propose a two-phase study in which R-A induction therapy is performed after R-M induction therapy in elderly patients with primary CNS lymphoma.
The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.
Systems and methods for separating mono nuclear cells from whole blood rotate a separation compartment (38) about a rotational axis. Whole blood is introduced from an inlet region (74) into a first region (76) of the chamber during its rotation to separte the whole blood into a plasma constituent, red blood cells and interphase between the red blood cells and the plasma constituent. The interface contains mono nuclear cells. While conveying whole blood into the first region, the plasma constituent is collected in the first region, while collecting the red blood cells in a second region of the chamber spaced away from the inlet region. Red blood cells are than conveyed into the second region (78) in a back flow direction toward the inlet region. While conveying red blood cells into the second region, the mono nuclear cells are collected in the first region.
PURPOSE:To obtain highly purified antibody in a short time in high yield with simple procedure, by adding ammonium sulfate to a specimen solution containing antibody, dissolving the obtained precipitate in an aqueous solution of ammonium sulfate having specific concentration, adsorbing the solution to a resin having hydrophobic group and eluting the adsorbed substance. CONSTITUTION:A precipitate produced by adding ammonium sulfate to a specimen solution containing antibody is dissolved in an aqueous solution having a concentration corresponding to <=20% of saturated concentration. The antibody and accompanied proteins in the solution are adsorbed in a resin having hydrophobic group (e.g. styrene resin). The adsorbed substances are eluted by using an aqueous solution of ammonium sulfate while continuously or stepwise decreasing the concentration from the concentration of the above aqueous solution of ammonium sulfate. The antibody can be purified in high purity by this process.
The incidence of ulcerative colitis (UC) is increasing annually, and UC has a serious impact on patients' lives. Polysaccharides have gained attention as potential drug candidates for treating ulcerative colitis (UC) in recent years. Huaier (Trametes robiniophila Murr) is a fungus that has been used clinically for more than 1000 years, and its bioactive polysaccharide components have been reported to possess immunomodulatory effects, antitumour potential, and renoprotective effects. In this study, we aimed to examine the protective effects and mechanisms of Huaier polysaccharide (HP) against UC. Based on the H2O2-induced oxidative stress model in HT-29 cells and the dextran sulphate sodium salt (DSS)-induced UC model, we demonstrated that Huaier polysaccharides significantly alleviated DSS-induced colitis (weight loss, elevated disease activity index (DAI) scores, and colonic shortening). In addition, HP inhibited oxidative stress and inflammation and alleviated DSS-induced intestinal barrier damage. It also significantly promoted the expression of the mucin Muc2. Furthermore, HP reduced the abundance of harmful bacteria Escherichia-Shigella and promoted the abundance of beneficial bacteria Muribaculaceae_unclassified, Anaerotruncus, and Ruminococcaceae_unclassified to regulate the intestinal flora disturbance caused by DSS. Nontargeted metabolomics revealed that HP intervention would modulate metabolism by promoting levels of 3-hydroxybutyric acid, phosphatidylcholine (PC), and phosphatidylethanolamine (PE). These results demonstrated that HP had the ability to mitigate DSS-induced UC by suppressing oxidative stress and inflammation, maintaining the intestinal barrier, and modulating the intestinal flora. These findings will expand our knowledge of how HP functions and offer a theoretical foundation for using HP as a potential prebiotic to prevent UC.
All healthy control participants will undergo the same screening and experimental procedures. Healthy controls must report no other medical conditions ( including fibromyalgia) to be considered for inclusion. All healthy controls will have an MRI scan performed both before and 3 hours post 0.4ng/kg endotoxin injection.
Patients receive TLR4 agonist GLA-SE intratumorally once weekly for 8 weeks. Within 2 weeks of starting treatment, patients also undergo radiation therapy over 2 weeks for a total of 5-6 fractions.
Of the total number of patients in clinical studies of SPY AGENT GREEN in visualization of vessels, blood flow and tissue perfusion, 7% were 65 and over, while 1% were 75 and over. Of the total number of patients in clinical studies of SPY AGENT GREEN in visualization of lymph nodes and lymphatic vessels during lymphatic mapping of cervical and uterine cancer, 9% were 65 and over, while 2% were 75 and over. Of the total number of patients in clinical studies of SPY AGENT GREEN in visualization of lymph nodes and lymphatic vessels during lymphatic mapping of breast cancer, 38% were 65 and over, while 8% were 75 and over.

No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between elderly and younger patients.

Clinical studies of SPY AGENT GREEN in visualization of extrahepatic biliary ducts did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This group will receive muscle energy technique along with routine physical therapy. This protocol will be given for 3 alternative days for 2 weeks . Each session will be of 50 mins. Data will be collected at baseline , at 1st week and at 2nd week.
Participants treated with guselkumab in one of the three primary studies (CNTO1959PUC3001 \[NCT06260163\], CNTO1959PBCRD3007 \[NCT05923073\], CNTO1275JPA3001 \[NCT05092269\]) will be enrolled in this LTE study, if in the investigator's opinion, the participant will benefit from continued guselkumab therapy. Participants will have continued access to guselkumab (q4w). Participants coming from the open-label arm of the primary studies will be assigned to q4w dosing. Participants coming from the jPsA primary study (CNTO1275JPA300) will continue the same dosing regimen from the primary study (q4w) and cannot increase their dose during the LTE study.